GSK Plc’s Chief Executive Officer Emma Walmsley is looking to do more deals as the British drugmaker doubles down on its ...

The anti-vaccine movement in the U.S. has gained momentum with President-elect Donald Trump's nomination of Robert F. Kennedy ...

GSK Plc CEO Emma Walmsley talks about buying US cancer biotech IDRx for as much as $1.15 billion, expanding their portfolio ...

GlaxoSmithKline (GSK) has appointed its consumer health leader, Emma Walmsley, to take over as CEO when Sir Andrew Witty retires next year. Walmsley has a background in marketing, and joined GSK ...

GSK plans five new product approvals by 2025, highlights strong specialty growth, and acquires IDRx for $1 billion to expand its oncology portfolio.

GlaxoSmithKline’s CEO Emma Walmsley has said the company hopes to get at least six new drug approvals in the next year. In an interview at the JP Morgan Healthcare Conference in San Francisco ...

Emma Walmsley, CEO of GSK, is nearly eight years into her effort to return the British pharma company to growth, and her work is starting to pay off. Much credit goes to Arexvy, GSK’s first-on ...

Walmsley stated that GSK's renewed focus on oncology is a strategic move to expand its specialty medicines portfolio. The company has plans to advance the IDRx drug to late-stage trials within the ...

Walmsley, the only woman CEO of a major pharma company, told Fortune at the time that GSK was working on building its vaccine portfolio. That’s not the only avenue where GSK is growing.

Emma Walmsley would like to see Prime Minister Narendra Modi creating a nutrition programme similar to the cleanliness drive Swachh Bharat. Get updates on your preferred social platform Follow us ...